22.418 articles found

Options in the treatment of motor fluctuations and dyskinesias in Parkinson's disease: a brief review.

Pahwa R, Lyons KE.

Neurol Clin · 2004-10-01

DOI: 10.1016/j.ncl.2004.06.007PMID: 15501365

Anxiety, depression, and psychosis in Parkinson's disease: unmet needs and treatment challenges.

Chen JJ.

Neurol Clin · 2004-10-01

DOI: 10.1016/j.ncl.2004.06.008PMID: 15501367

Session 3 "Analyzer Workshop" evolution of therapeutic strategies in Parkinson's disease.

Yanagisawa N, Yamamoto M, Kikuchi S, Murata M, Ohkuma Y.

J Neurol · 2004-10-01

DOI: 10.1007/s00415-004-1707-2PMID: 15505751

Effect of levodopa treatment for parkinsonism in welders: a double-blind study.

Chu NS.

Neurology · 2004-10-01

DOI: 10.1212/wnl.63.8.1541PMID: 15505194

Treatment of nocturnal disturbances and excessive daytime sleepiness in Parkinson's disease.

Barone P, Amboni M, Vitale C, Bonavita V.

Neurology · 2004-10-01

DOI: 10.1212/wnl.63.8_suppl_3.s35PMID: 15505142

Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implications.

Hanson GR, Sandoval V, Riddle E, Fleckenstein AE.

Ann N Y Acad Sci · 2004-10-01

DOI: 10.1196/annals.1316.019PMID: 15542712

Embryonic stem cells: a promising tool for cell replacement therapy.

Doss MX, Koehler CI, Gissel C, Hescheler J, Sachinidis A.

J Cell Mol Med · 2004-10-01

DOI: 10.1111/j.1582-4934.2004.tb00471.xPMID: 15601575

Cell therapy in Parkinson's disease.

Lindvall O, Björklund A.

NeuroRx · 2004-10-01

DOI: 10.1602/neurorx.1.4.382PMID: 15717042

Immune problems in central nervous system cell therapy.

Barker RA, Widner H.

NeuroRx · 2004-10-01

DOI: 10.1602/neurorx.1.4.472PMID: 15717048

Treatment of spasticity with botulinum toxin.

Baba M D Y, Osborne M D MD, Wszolek M D ZK, Kwolek A, Druzbicki Ph D M.

Ortop Traumatol Rehabil · 2004-10-01

PMID: 17618218

Mitochondrial dysfunction and possible treatments in Parkinson's disease--a review.

Shults CW.

Mitochondrion · 2004-09-29

DOI: 10.1016/j.mito.2004.07.028PMID: 16120421

COMBINATION THERAPY FOR THE TREATMENT OF PARKINSONaCOES DISEASE WITH CYCLOOXYGENASE-2 (COX 2) INHIBITOR(S).

TIMOTHY J MAZIASZ.

· 2004-09-24